Recaticimab and Adebrelimab with chemo for advanced bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two targeted drugs (Recaticimab and Adebrelimab) plus chemotherapy for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of bile duct or gallbladder cancer that has spread or cannot be removed with surgery.
- You cannot have had any previous chemotherapy or immunotherapy for advanced cancer, except if it's been more than 6 months since finishing treatment after surgery.
- Your cancer must be measurable on a scan (at least 1 cm in size).
- Your liver function must be good (Child-Pugh class A) and you must be able to perform daily activities (ECOG score 0-1).
- You cannot have active other cancers, serious infections, or uncontrolled health problems like bleeding or blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three medicines (adebrelimab, apatinib, and standard chemotherapy) for people with newly diagnosed bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if the combination can shrink the tumor and make it possible to remove later.
This trial tests a combination of four drugs (adebrelimab, apatinib, gemcitabine, and cisplatin) as a first treatment for people with advanced or metastatic bile duct cancer that cannot be removed by surgery. The goal is to see if this combination helps shrink or control the cancer.
This study tests adding the immunotherapy adebrelimab to standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for advanced biliary tract cancer that can't be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial is for people with bile duct cancer who have had surgery to remove all visible cancer but are at high risk of it coming back. It tests whether adding two medications — adebrelimab (an immunotherapy) and capecitabine (a chemotherapy pill) — after surgery can help prevent the cancer from returning.
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
Hear when a new Biliary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.